



Universiteit
Leiden
The Netherlands

Renin-angiotensin system pathway therapeutics associated with improved outcomes in males hospitalized with COVID-19*

Rocheleau, G.L.Y.; Lee, T.; Mohammed, Y.; Goodlett, D.; Burns, K.; Cheng, M.P.; ... ; ARBs
CORONA I Investigators

Citation

Rocheleau, G. L. Y., Lee, T., Mohammed, Y., Goodlett, D., Burns, K., Cheng, M. P., ... Russell, J. A. (2022). Renin-angiotensin system pathway therapeutics associated with improved outcomes in males hospitalized with COVID-19*. *Critical Care Medicine*, 50(9), 1306-1317.
doi:10.1097/CCM.0000000000005589

Version: Publisher's Version
License: [Creative Commons CC BY-NC-ND 4.0 license](https://creativecommons.org/licenses/by-nc-nd/4.0/)
Downloaded from: <https://hdl.handle.net/1887/3513401>

Note: To cite this publication please use the final published version (if applicable).

Renin-Angiotensin System Pathway Therapeutics Associated With Improved Outcomes in Males Hospitalized With COVID-19*

OBJECTIVES: To determine whether angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme (ACE) inhibitors are associated with improved outcomes in hospitalized patients with COVID-19 according to sex and to report sex-related differences in renin-angiotensin system (RAS) components.

DESIGN: Prospective observational cohort study comparing the effects of ARB or ACE inhibitors versus no ARBs or ACE inhibitors in males versus females. Severe acute respiratory syndrome coronavirus 2 downregulates ACE-2, potentially increasing angiotensin II (a pro-inflammatory vasoconstrictor). Sex-based differences in RAS dysregulation may explain sex-based differences in responses to ARBs because the *ACE2* gene is on the X chromosome. We recorded baseline characteristics, comorbidities, prehospital ARBs or ACE inhibitor treatment, use of organ support and mortality, and measured RAS components at admission and days 2, 4, 7, and 14 in a subgroup ($n = 46$), recorded D-dimer ($n = 967$), comparing males with females.

SETTING: ARBs CORONA I is a multicenter Canadian observational cohort of patients hospitalized with acute COVID-19. This analysis includes patients admitted to 10 large urban hospitals across the four most populated provinces.

PATIENTS: One-thousand six-hundred eighty-six patients with polymerase chain reaction-confirmed COVID-19 (February 2020 to March 2021) for acute COVID-19 illness were included.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Males on ARBs before admission had decreased use of ventilation (adjusted odds ratio [aOR] = 0.52; $p = 0.007$) and vasopressors (aOR = 0.55; $p = 0.011$) compared with males not on ARBs or ACE inhibitors. No significant effects were observed in females for these outcomes. The test for interaction was significant for use of ventilation ($p = 0.006$) and vasopressors ($p = 0.044$) indicating significantly different responses to ARBs according to sex. Males had significantly higher plasma ACE-1 at baseline and angiotensin II at day 7 and 14 than females.

CONCLUSIONS: ARBs use was associated with less ventilation and vasopressors in males but not females. Sex-based differences in RAS dysregulation may contribute to sex-based differences in outcomes and responses to ARBs in COVID-19.

KEY WORDS: angiotensin receptor blockers; angiotensin-converting enzyme 2; angiotensin-converting enzyme inhibitors; COVID-19; sex differences

The renin-angiotensin system (RAS) regulates blood pressure and water balance, as well as important roles in renal function, homeostasis, fibrosis, and inflammation. Angiotensin-converting enzyme (ACE)-2 converts angiotensin II to angiotensin 1–7 (1–3). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein downregulates ACE-2 (4),

Genevieve L. Y. Rocheleau, MSc¹
Terry Lee, PhD²

Yassene Mohammed, PhD^{3,4}

David Goodlett, PhD^{3,5,6}

Kevin Burns, MD⁷

Matthew P. Cheng, MD⁸

Karen Tran, MD⁹

David Sweet, MD¹⁰

John Marshall, MD¹¹

Arthur S. Slutsky, MD¹¹

Srinivas Murthy, MD¹²

Joel Singer, PhD²

David M. Patrick, MD¹³

Bin Du, MD¹⁴

Zhiyong Peng, MD¹⁵

Todd C. Lee, MD⁸

John H. Boyd, MD^{1,16}

Keith R. Walley, MD^{1,16}

Francois Lamontagne, MD¹⁷

Robert Fowler, MD¹⁸

Brent W. Winston, MD¹⁹

Greg Haljan, MD²⁰

Donald C. Vinh, MD⁸

Alison McGeer, MD²¹

David Maslove, MD²²

Santiago Perez Patrigeon, MD²²

Puneet Mann, MSc²³

Kathryn Donohoe, BSc²³

Geraldine Hernandez, BSc²³

James A. Russell, MD^{1,16}

for ARBs CORONA I Investigators

*See also p. 1396.

Copyright © 2022 The Author(s).
Published by Wolters Kluwer Health,
Inc. on behalf of the Society of Critical
Care Medicine and Wolters Kluwer
Health, Inc. This is an open-access article
distributed under the terms of the
Creative Commons Attribution-Non
Commercial-No Derivatives License 4.0
(CCBY-NC-ND), where it is permissible
to download and share the work provided
it is properly cited. The work cannot be
changed in any way or used commercially
without permission from the journal.

DOI: 10.1097/CCM.0000000000005589

decreasing conversion of angiotensin II to angiotensin 1–7 (1–3) that could increase angiotensin II levels, which worsens lung injury in influenza (**Supplemental Fig. S1**, <http://links.lww.com/CCM/H133>) (5, 6) and SARS models (7). Plasma angiotensin II levels are increased in influenza and are associated with influenza viral load and mortality (8). Angiotensin II levels are increased in some COVID-19 studies but not universally in COVID-19 (9–12).

Angiotensin receptor blockers (ARBs) block angiotensin II receptor 1 (13, 14) countering angiotensin II's effects. ACE inhibitors block conversion of angiotensin I to angiotensin II possibly mitigating angiotensin II in COVID-19. ARBs and ACE inhibitors are commonly used in hypertension (59%) (15), chronic kidney disease (CKD) (16), and diabetes (32%) (17). ARBs and ACE inhibitors target the RAS pathway by different mechanisms and could have different effects in COVID-19.

Trials of ARBs or ACE inhibitors differ: in one trial (18) of patients who were not on ARBs or ACE inhibitors previously who were then randomized to ARBs or not, patients on ARBs had significantly lower mortality. In contrast, trials of continuing or not continuing ARBs in patients already on those drugs found no differences in mortality between groups (19). These trials were all done in mild to moderately ill acute COVID-19 patients.

Males are a higher proportion of hospitalizations (e.g., 54% of cases), ICU admissions (64%), and deaths (57%) in COVID-19 (20–22). However, the biological cause (23, 24) of this differential risk remains unknown. Furthermore, the response to ARBs and ACE inhibitors according to sex has not been reported.

Sex differences in the RAS could explain worse male outcomes with COVID-19. *ACE-2* gene is on the X chromosome, so *ACE-2* X-inactivation in males versus females could cause sex-based differences of COVID-19 outcomes (25). Plasma *ACE-2* is higher in males with kidney disease (26), diabetes (27, 28) and are associated with COVID-19 mortality (29).

We hypothesized that ARBs and ACE inhibitors improve outcomes in hospitalized COVID-19 patients according to sex and that sex-related differences in RAS components contribute to sex disparity in outcomes. This was an a priori hypothesis of a Canadian Institutes of Health Research grant in acute COVID-19 (30).

MATERIALS AND METHODS

Patient Population

ARBs CORONA I is a Canadian multisite observational cohort study comparing the effects of ARBs or ACE inhibitor use on outcomes of acute COVID-19 (ClinicalTrials.gov Identifier: NCT04510623). Patients with a positive polymerase chain reaction test admitted to hospital for acute COVID-19 were included. We excluded emergency department visits not requiring admission, those admitted to hospital but not due to acute COVID-19, acute COVID-19 readmissions, those with unknown discharge outcome, and those who remained hospitalized at the time of data censoring (July 10, 2021).

Data Collected

We recorded baseline characteristics, comorbidities (CKD, chronic cardiac disease, diabetes, hypertension), prehospital treatment with ARBs or ACE inhibitors, use of ventilation, vasopressors, and renal replacement therapy (RRT), 28-day and hospital mortality, and ICU and hospital length of stay. Patients were divided into ARBs or ACE inhibitors groups based on chart review and whether current ARBs or ACE inhibitor use was documented at hospital intake. If no ARBs or ACE inhibitor use was recorded, then the patient was classified as a no ARBs or ACE inhibitor control. Discarded clinical EDTA-plasma was collected at baseline (admission = day 0) and days 2, 4, 7, and 14 and stored in at -80°C in a randomly chosen subgroup of patients. For the longitudinal analyses, plasma was collected at days 0, 2, 4, 7, and 14 during hospitalization but no plasma samples were obtained after hospital discharge.

Justification for Use of Clinical Outcomes

Studies of acute COVID-19 report progression to critical care (ICU admission) and mortality, so we strengthened results by evaluating critical care support (i.e., ventilation, vasopressors, and RRT). As in the World Health Organization COVID-19 ordinal outcome scale (31), we assessed ventilation, vasopressors, and RRT (32, 33). We evaluated 28-day mortality because it is the pivotal endpoint for most randomized controlled trials (RCTs) in sepsis (34, 35).

Ethics

This study was approved by Providence Health Care and University of British Columbia Human Research Committee (H20-00600). Anonymized clinical data and use of discarded plasma from clinical blood tests were deemed low risk and informed consent was not required.

Renin-Angiotensin System Components

Plasma RAS components were measured in duplicate by enzyme-linked immunosorbent assays using commercial suppliers (**Supplemental Methods S2**, <http://links.lww.com/CCM/H133>) as per prior protocols (36, 37).

Statistical Analysis of Clinical Outcomes

We compared males' versus females' outcomes using logistic regression for binary outcomes and Cox regression for time to event. Regression models included sex and prehospital ARBs or ACE inhibitor usage as independent variables, site (to account for site differences in management), and ARBS CORONA I predefined adjustment variables: age, admission systolic blood pressure, chronic cardiac disease, hypertension, CKD, and diabetes. Results were expressed as adjusted odds ratio (aOR) or adjusted hazard ratio (aHR). The adjustment variables are from baseline values defined as the first available data within 24 hours of admission.

Separately analyzed, we added an interaction term between sex and prehospital ARBs or ACE inhibitor use to assess the association of prehospital ARBs or ACE inhibitor use and outcomes by sex and test for homogeneity between males and females. We further adjusted for admission creatinine level because it was different between ARBs or ACE inhibitor users and nonusers within each sex group.

Patients discharged alive prior to day 28 and lost to follow-up were assumed 28-day survivors. For time to hospital discharge, deaths prior to discharge were considered as never discharged and censored at largest observed length of stay. Results were not adjusted for multiple comparisons given the hypothesis-generating nature of the study. Missing data was minimal, so patients with missing data were excluded from the corresponding analysis.

Statistical Analysis of Renin-Angiotensin System Components

Plasma levels of RAS components were not normally distributed, so nonparametric statistics were used. Adjusted analyses based on quantile regression were performed to compare the median plasma RAS component levels at baseline between sexes after adjustment for age, chronic cardiac disease, CKD, diabetes, and hypertension. Due to limited sample size, comparison of plasma RAS component levels on days 2, 4, 7, and 14 were unadjusted for confounders and was based on linear quantile mixed regression with patient-specific random effect (<https://www.jstatsoft.org/article/view/v057i13>).

RESULTS

Patient Characteristics

Of 2,088 patients in ARBs I admitted between February 28, 2020, and April 14, 2021, we excluded emergency department visits not requiring hospital admission ($n = 125$), those admitted to hospital not due to acute COVID-19 ($n = 220$), acute COVID-19 readmissions ($n = 37$), those with unknown discharge outcome or currently still hospitalized ($n = 19$), and patient's sex being unspecified ($n = 1$) (**Table 1**). The final sample size was 1,686 (1,027 males, 658 females); 64% were not taking ARBs or ACE inhibitors at admission (658 males, 428 females), 18% were on ARBs at admission (177 males, 119 females), and 18% were on ACE inhibitors at admission (192 males, 112 females) (**Supplemental Fig. S3**, <http://links.lww.com/CCM/H133>). Patients on either ARBs or ACE inhibitors had more comorbidities than patients not on ARBs or ACE inhibitors in both males and females (**Supplemental Table S4**, <http://links.lww.com/CCM/H133>); 53.3% (320/600) continued on ARBs or ACE inhibitors after admission (male: 190/369 [52%], female: 130/231 [56%]).

Comparison of Males to Females

Males had significantly more chronic cardiac disease and a higher serum creatinine at baseline than females (Table 1; and **Supplemental Tables S4** and **S5**, <http://links.lww.com/CCM/H133>). Males had significantly greater adjusted odds of inhospital mortality (1.46; 95% CI = 1.11–1.93; $p = 0.008$), ICU admission (aOR = 1.46; 95% CI = 1.14–1.86; $p = 0.003$), use of ventilation

TABLE 1.
Baseline Characteristics of Patients Hospitalized for COVID-19

Variable	All (<i>n</i> = 1,686)	Sex		<i>p</i>
		Male (<i>n</i> = 1,027)	Female (<i>n</i> = 659)	
Admission date, <i>n</i> (%)				0.481
March 2020 to May 2020	475 (28.2)	276 (26.9)	199 (30.2)	
June 2020 to August 2020	58 (3.4)	35 (3.4)	23 (3.5)	
September 2020 to November 2020	356 (21.1)	228 (22.2)	128 (19.4)	
December 2020 to February 2021	565 (33.5)	342 (33.3)	223 (33.8)	
March 2021 to April 2021	232 (13.8)	146 (14.2)	86 (13.1)	
COVID-19 confirmed status, <i>n</i> (%)				0.360
Positive—screening test	82 (4.9)	46 (4.5)	36 (5.5)	
Positive—definitive test	1,604 (95.1)	981 (95.5)	623 (94.5)	
Positive for other pathogen, <i>n</i> (%)	37 (2.2)	25 (2.4)	12 (1.8)	0.402
Sex, <i>n</i> (%)				—
Male	1,027 (60.9)	1,027 (100.0)	0 (0.0)	
Female	659 (39.1)	0 (0.0)	659 (100.0)	
Age				0.158
Mean (sd)	65.6 (16.7)	65.2 (15.9)	66.3 (17.8)	
Median (IQR)	67.0 (55.0–78.0)	66.0 (55.0–77.0)	69.0 (54.0–81.0)	
Range	(19.0–103.0)	(19.0–100.0)	(22.0–103.0)	
Comorbidities, <i>n</i> (%)				
Any of the four below	1,131/1,680 (67.3)	691/1,022 (67.6)	440/658 (66.9)	0.751
Chronic cardiac disease	422/1,673 (25.2)	282/1,018 (27.7)	140/655 (21.4)	0.004
Chronic kidney disease	239/1,681 (14.2)	152/1,022 (14.9)	87/659 (13.2)	0.338
Hypertension	890/1,679 (53.0)	548/1,022 (53.6)	342/657 (52.1)	0.530
Diabetes	560/1,679 (33.4)	349/1,021 (34.2)	211/658 (32.1)	0.369
Arterial oxygen saturation (%), mean (sd)	90.4 (9.0)	90.2 (8.9)	90.7 (9.3)	0.241
Missing, <i>n</i>	17	11	6	
Creatinine (μmol/L), median (IQR)	86 (69–116)	92 (76–127)	73 (59–99)	<0.001
Missing, <i>n</i>	29	17	12	
D-dimer level (ng/mL), median (IQR)	839 (508–1,600)	857 (512–1,590)	815 (503–1,600)	0.937
Missing, <i>n</i>	967	601	366	

IQR = interquartile range.

(aOR = 1.54; CI = 1.20–1.99; *p* < 0.001), and use of vasopressors (aOR = 1.58; CI = 1.23–2.03; *p* < 0.001) compared with females (Fig. 1; and Supplemental Table S6, <http://links.lww.com/CCM/H133>).

ARBs Versus No ARBs: Within Sex Comparison and Test for Interaction Between Sexes

Males on ARBs had decreased use of ventilation (aOR = 0.52; CI = 0.32–0.83; *p* = 0.007) and decreased

use of vasopressors (aOR = 0.55; CI = 0.34–0.87; *p* = 0.011) compared with males not on ARBs or ACE inhibitors, but no significant effects of ARBs were observed in females for these outcomes (Fig. 2; and Supplemental Table S7, <http://links.lww.com/CCM/H133>; aOR = 1.33; CI = 0.76–2.30 for ventilation and aOR = 1.08; CI = 0.63–1.87 for use of vasopressors).

Test for interaction between males and females was significant for use of mechanical ventilation

($p = 0.006$) and use of vasopressors ($p = 0.044$) indicating significantly different responses to ARBs between sexes. Time to discharge was also significantly shorter for males on ARBs versus those not on ARBs (aHR = 1.35; CI = 1.08–1.70; $p = 0.009$; median time to discharge, 17 vs 21 d). The aHR in females was similar to males (aHR = 1.27; CI = 0.97–1.66; $p = 0.077$; median time to discharge, 15 vs 19 d) and the test for interaction between males and females was not significant ($p = 0.706$).

ACE Inhibitors Versus No ACE Inhibitors: Within Sex Comparison and Test for Interaction Between Sexes

There were no differences in mortality and other outcomes of males on ACE inhibitors versus males not on ARBs or ACE inhibitors (Fig. 2; and Supplemental Table S7, <http://links.lww.com/CCM/H133>). There were also no significant effects of ACE inhibitors in females for these outcomes.

ARBs Versus ACE Inhibitors

There was some evidence that the effect of ARBs was different from that of ACE inhibitors in females for use of invasive ventilation (aOR = 1.96; CI = 0.99–3.88;

$p = 0.054$; Fig. 3, Supplemental Table S7, <http://links.lww.com/CCM/H133>). Males on ARBs alone had significantly shorter time to discharge compared with males on ACE inhibitors (aHR = 1.33; CI = 1.02–1.72; $p = 0.034$; median time to discharge, 17 vs 21 d).

Plasma Levels of RAS Components and D-Dimer

Plasma RAS component levels were measured in a random subgroup of patients (Fig. 4; and Supplemental Table S8, <http://links.lww.com/CCM/H133>). Baseline plasma ACE-1 was significantly higher in males ($n = 33$) than females ($n = 13$) (estimated difference in median = 78.1 ng/mL; CI = 3.2–153.0; $p = 0.042$) (Fig. 4A). There was no significant difference in ACE-2 levels between males and females. Angiotensin II was significantly higher in males compared with females on day 7 (median: 109.1 vs 66.2; $p = 0.047$) and 14 (median: 126.4 vs 42.7; $p < 0.001$) of hospitalization (Fig. 4B). Sample size was inadequate to test for differences in RAS components between patients on or not on ARBs or ACE inhibitors.

There were no differences in baseline plasma D-dimer levels between males (median interquartile range [IQR] = 857 [508–1,600]) and females (median [IQR] = 815 [503–1,600]; $p = 0.937$) (Table 1).

DISCUSSION

Males hospitalized with acute COVID-19 had worse outcomes than females. Our novel, more clinically relevant finding was that males on ARBs had better outcomes than males not on ARBs but females did not. Our finding higher plasma ACE-1 and angiotensin II level in males versus females is also novel, suggesting sex-related RAS dysregulation in acute COVID-19.




Figure 1. Males experience significantly worse clinical outcomes compared with females overall. Forest plot indicating results of separate regression analyses in form of multivariable logistic regression for binary outcomes (adjusted odds ratios) and Cox regression for “time to” outcomes (adjusted hazard ratios), as well as 95% CIs (x-axis), comparing males and females overall. Vertical dashed line indicates adjusted odds ratio of 1. See Methods for list of adjustment variables.




Figure 2. Prehospital angiotensin receptor blockers (ARBs) show protective effects within males: use of ventilation and vasopressors were significantly less than males not on prehospital ARBs or angiotensin-converting enzyme inhibitors (ACEi), and the effect was significantly greater than within females. Forest plot showing within sex comparison odds ratios/hazard ratios of clinical outcomes for those on ARBs (first column), ACEi (second column), or on either ARBs or ACEi (third column) versus those not on ARBs or ACEi, respectively. See Methods for list of adjustment variables. Test for homogeneity p values are included, indicating comparisons where males were significantly different than females.

Males had more frequent acute respiratory distress syndrome (ARDS), RRT use, and greater length of mechanical ventilation and hospital stay and higher hospital mortality than females in another study (38). Globally, males account for a higher proportion of hospitalizations, ICU admissions, and deaths (20).

We proposed a priori and confirmed herein that males on ARBs (but not ACE inhibitors) had lower mortality than males not on ARBs. Meta-analyses (39) report that use of ARBs and ACE inhibitors in COVID-19 is associated with decreased mortality. None have

reported associations of ARBs or ACE inhibitors with outcomes of COVID-19 in males versus females.

RCTs of ARBs and ACE inhibitors do not address male versus female responses. Three RCTs compared an ARB to standard of care, two underpowered with nonsignificant findings (40, 41). Telmisartan significantly decreased ICU admission, ventilation and death in one small RCT with a higher proportion of males in the telmisartan versus control group (18). However, there is no direct report of sex-based differences in responses to ARBs or ACE inhibitors.




Figure 3. There were varying effects of angiotensin receptor blockers (ARBs) compared with ACE inhibitors (ACEi) within different sexes. Males on ARBs had significantly shorter time to discharge compared with males on ACEi, whereas females on ARBs were significantly more likely to use ventilation than females on ACEi. Forest plot showing within sex comparison odds ratios/hazard ratios of clinical outcomes for those on ARBs versus those on ACEi. See Methods for list of adjustment variables. Test for homogeneity *p* values are included, indicating the protective effect of ARBs compared with ACEi was significantly greater among males compared with among females, in use of ventilation and use of vasopressor outcomes.

Our analysis is novel and adds to the literature by providing unique insights about why males with acute COVID-19 do worse and the first discovery that males respond better to prior ARBs use than females. Trials of ARBs or ACE inhibitors differ: In one trial (18) of patients who were not on ARBs or ACE inhibitors previously who were then randomized to ARBs or not, patients on ARBs had significantly lower mortality. In contrast, trials of continuing or not continuing ARBs in patients already on those drugs found no differences in mortality between groups (19).

Sex-related differences in ARBs' responses occur in hypertension, and there are improved responses to ARBs in males in hypertension RCTs. In a large meta-analysis, seven of nine trials found ACE inhibitor or

ARBs more beneficial in males than females (42).

A fundamental question is whether differences in outcomes between those taking and not taking ARB or ACE inhibitors is related to the patient rather than the drug. Supplemental Table S4 (<http://links.lww.com/CCM/H133>) shows baseline characteristics stratified by sex (since the final regression models compared within sex also) comparing no ARBs or ACE inhibitor, ACE inhibitor, and ARBs. While there were some differences between patients on ARBs or ACE inhibitor and those not (e.g., males not on ARBs or ACE inhibitor had significantly lower systolic blood pressure than those on ARBs and ACE inhibitor), the adjusted regression model took these patient baseline characteristics into account (Supplemental Tables S6 and S7, <http://links.lww.com/CCM/H133>). Thus,

we suggest that the differences between patients taking versus not taking ARBs and ACE inhibitors is associated with the drugs.

To understand mechanisms for differences in outcomes of males and females, we evaluated RAS components and D-dimers and found higher plasma levels of ACE-1 and angiotensin II in males than females but no differences between sexes in D-dimer levels.

Proposed mechanisms for sex-related differences of COVID-19 include that ACE-2 (the main SARS-CoV-2 receptor) is on the X chromosome and incomplete X chromosome activation could cause sex differences in ACE-2 expression. Transmembrane protease, serine 2 (TMPRSS2) is also required for SARS-CoV-2 cell entry [23, 24]). Androgens regulate TMPRSS2 (43) perhaps

Downloaded from <http://journals.lww.com/ccmjournal> by BNDM5ePHKav1ZEumt1QIN4ak+LhEz9gsIH04XM10hCy wCX1AWnYQp/1QIH-D3D0DQFRyITvSF14Cf3V/C4/OAAVpDDa8KKGKVOYmy+78= on 11/22/2023




Figure 4. Males' renin-angiotensin system (RAS) component levels compared with those of females hospitalized with COVID-19 at baseline (day 0), day 2, 4, 7, and 14. **A**, Baseline adjusted median difference in RAS component levels males versus females based on quantile regression adjusting for age, chronic cardiac disease, chronic kidney disease, diabetes, and hypertension ($n = 46$).

B, Comparison of RAS component levels between sexes over time based on adjusted quantile regression (day 0) and linear quantile mixed regression (day 2 and onward; unable to adjust for other variables due to small sample size). ACE = angiotensin-converting enzyme.

altering SARS-CoV-2 uptake in males versus females. We could not assess TMPRSS2 levels in this clinical study.

A recent study (12) found that angiotensin II levels decreased over time in severe COVID-19 suggesting decreased systemic catalytic activity over time following inflammatory ACE-1 shedding from the endothelium. Another recent study (44) found prominent but delayed elevations in renin and ACE-2 among more severely ill patients. Another series (45) reports increases in ACE-2 over time that are not unique to COVID ARDS.

Our findings of higher plasma ACE-1 and angiotensin II in males versus females is novel. No studies of plasma angiotensin II levels in COVID-19 (9–12) compare males to females. High angiotensin II levels

are associated with prolonged viral shedding (45), human influenza (8), and worse lung injury (6) possibly explaining why we found that males on ARBs had better outcomes than males not on ARBs; our RAS subgroup sample size was underpowered to evaluate ARBs interaction according to sex.

Females have less frequent thromboembolic complications of COVID-19 compared with males (46). However, we did not find sex-related differences in plasma D-dimer levels.

Strengths of our study are the novel biological sex hypothesis, multicenter design, large sample size, and evaluation of sex-based differences in response to ARBs or ACE inhibitors. Originally the ARBs CORONA I cohort study had a relatively conservative enrollment target based on early estimates

of frequency and prevalence of COVID-19. The COVID-19 pandemic rapidly grew, we secured increased funding and converted our cohort from a closed to an open cohort to increase power and generalizability.

Limitations are that our observational cohort cannot prove causation. Differences based on long-term ARBs and ACE inhibitor use may reflect the underlying cardiorenal vascular disease for which ARBs and ACE inhibitors are prescribed, the degree of chronic disease progression, and adequacy of disease control. Given the multiple indications for treatment (e.g., hypertension, renal protection, myocardial anti-remodeling), it is difficult to adjust for indication severity and/or adequacy of control. Additionally, although hypertension was included in our regression models, other non-ARBs or ACE inhibitor antihypertensive medications were not accounted for and may be confounding factors. Another limitation was the numbers of events on the day of admission were limited; however, there were a sizeable number of patients with events over the course of hospitalization. For example, 62 males on ARBs received vasopressors and 63 males on ARBs received ventilation. We also investigated levels of RAS pathway components over 14 days in hospital and found plasma ACE-1 and angiotensin II were higher in males; however, the sample size and power were limited. Renin, ACE-1, and ACE-2 have high catalytic activity in plasma. Because of this high enzymatic activity, the levels of angiotensinogen metabolites may also be impacted by factors such as time from sample collection, ambient temperature, and plasma pH. Best practice when measuring these metabolites is to limit the amount of time before freezing and/or to add enzymatic inhibitors to stabilize the sample (19). We acknowledge the potentially significant risk of measurement error for angiotensin I, angiotensin II, and angiotensin 1–7. Also, our results were focused on biological sex and not gender and so it was beyond the scope of our study to explore the effects of gender but that may also be an important in COVID-19 and response to ARBs and ACE inhibitors. And finally, chronic RAS blocker therapies may also be in part a proxy for how frequently and how well patients access the healthcare system. This study was done in Canada that has a universal healthcare system, and while this does not remove all barriers, it does address some disparities. We do recognize that the

longitudinal management of chronic disease may also drive our finding associations according to sex with better outcomes.

There was considerable controversy around early versus conservative intubation in acute COVID-19. Unfortunately, we do not know local practices regarding intubation, which is an additional limitation that may have impacted the event rate for invasive ventilation.

CONCLUSIONS

Males hospitalized with COVID-19 had worse clinical outcomes than females. Prehospital ARBs use—but not ACE inhibitor use—was associated with significantly better clinical outcomes in males but not in females. While the main insights of our study are the clinical outcomes according to sex and use of ARBs or ACE inhibitors, the RAS pathway component analyses suggest but do not prove a possible mechanism of the clinical findings.

ACKNOWLEDGMENTS

We thank the investigators in the Angiotensin Receptor Blockers (ARBs) CORONA I study and their teams for their ongoing support and tireless collaboration. The technical assistance of Mr. Joseph Zimpelmann, University of Ottawa, in performing enzyme-linked immunosorbent assays is gratefully acknowledged. We thank the patients and families who participated in the ARBs CORONA I study, which has increased our understanding of COVID-19. We also thank the many dedicated clinicians (doctors, nurses, therapists, and others) who cared for these patients and comforted their families.

- 1 Centre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
- 2 Centre for Health Evaluation and Outcome Science (CHEOS), St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
- 3 University of Victoria, Genome BC Proteomics Centre, Victoria, BC, Canada.
- 4 Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
- 5 Department of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada.
- 6 International Centre for Cancer Vaccine Science, University of Gdansk, Gdansk, Poland.

- 7 Division of Nephrology, Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.
- 8 Divisions of Infectious Diseases & Medical Microbiology, McGill University Health Center, McGill's Interdisciplinary Initiative in Infection and Immunity, Montreal, QC, Canada.
- 9 Division of General Internal Medicine, Vancouver General Hospital and University of British Columbia, Vancouver, BC, Canada.
- 10 Division of Critical Care Medicine, Vancouver General Hospital, Vancouver, BC, Canada.
- 11 Department of Surgery, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
- 12 British Columbia Children's Hospital, University of British Columbia, Vancouver, BC, Canada.
- 13 British Columbia Centre for Disease Control (BCCDC), and School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada.
- 14 Medical ICU, Peking Union Medical College Hospital, Beijing, China.
- 15 Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
- 16 Division of Critical Care Medicine, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
- 17 University of Sherbrooke, Sherbrooke, QC, Canada.
- 18 Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
- 19 Departments of Critical Care Medicine, Medicine and Biochemistry and Molecular Biology, University of Calgary, Calgary, AB, Canada.
- 20 Department of Medicine, Surrey Memorial Hospital, Surrey, BC, Canada.
- 21 Mt. Sinai Hospital and University of Toronto, Toronto, ON, Canada.
- 22 Department of Medicine, Kingston General Hospital and Queen's University, Kingston, ON, Canada.
- 23 Black Tusk Research Group Inc., Vancouver, BC, Canada.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (<http://journals.lww.com/ccmjjournal>).

Supported, in part, by grant from the Canadian Institutes of Health Research (CIHR Number 439993) and by the St. Paul's Hospital Foundation. This study was supported by a grant from the CIHR (grant number 442999: "Host Response Mediators in Coronavirus (2019-nCoV) Infection—Is There a Protective Effect of Angiotensin II Type 1 Blockers on Outcomes of Coronavirus Infection?" and "Sex Differences in Outcomes of COVID-19") to Dr. Russell.

Drs. Rocheleau's, Cheng's, Lee's, Haljan's, Vinh's, Mann's, Donohoe's, and Russell's institutions received funding from the Canadian Institutes for Health Research. Dr. Mohammed's institution received funding from Genome Canada and Genome British Columbia. Dr. Goodlett disclosed that he is the founder of Pataigin LLC and Deurion LLC and that the University of Victoria Genome British Columbia Proteome Centre (for which he is a director) received funding from Genome Canada and Genome

British Columbia. Dr. Burns disclosed that he is a consultant to JN Nova Pharma. Dr. Cheng's institution received funding from McGill Interdisciplinary Initiative in Infection and Immunity; he received funding from GEn1E Lifesciences and NPLex Biosciences; he disclosed that he is the cofounder of Kanvas Biosciences and owns equity in the company; and he disclosed that he is a named coinventor on a pending patent entitled "Methods for assessing the severity and progression of SARS-CoV2 infections using cell-free DNA." Dr. Slutsky received funding from Apeiron, GlaxoSmithKline, Baxter, Cellenkos, Diffusion, Edesa, Exvastat, Faron, and Novalung. Dr. Lee received funding from the Fonds de recherche du Quebec santé (FRQS). Dr. Haljan's institution received funding from Michael Smith Foundation for Health Research and Surrey Hospital Foundation. Dr. Vinh's institution received funding from the Jeffrey Modell Foundation and FRQS; he received funding from CSL Behring, Astra Zeneca, Moderna, Takeda, QU Biologics, Merck Canada, Novartis Canada, and the COVID Immunity Task Force (Public Health Agency of Canada); he disclosed he has patent applications pending (Encrypting File System Identification [EFS ID] 40101099; EFS ID 44321620). Dr. Russell reports patents owned by the University of British Columbia (UBC) that are related to the use of proprotein convertase subtilisin/kexin type 9 inhibitor(s) in sepsis and related to the use of vasopressin in septic shock and a patent owned by Ferring for use of selepressin in septic shock; he is an inventor on these patents; he was a founder, director, and shareholder in Cyon Therapeutics and is a shareholder in Molecular You Corp; he reports receiving consulting fees in the last 3 years from: Asahi Kesai Pharmaceuticals of America (was developing recombinant thrombomodulin in sepsis), SIB Therapeutics LLC (developing a sepsis drug), and Ferring Pharmaceuticals (manufactures vasopressin and developing selepressin); he is no longer actively consulting for the following: La Jolla Pharmaceuticals (developing angiotensin II); Dr. Russell chaired the Data Safety Monitoring Board of a trial of angiotensin II from 2015 to 2017), PAR Pharma (sells prepared bags of vasopressin); and he reports having received an investigator-initiated grant from Grifols (entitled "Is HBP a mechanism of albumin's efficacy in human septic shock?") that was provided to and administered by UBC. The remaining authors have disclosed that they do not have any potential conflicts of interest.

Address requests for reprints to: James A. Russell, MD, Centre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, 1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6. E-mail: Jim.Russell@hli.ubc.ca

REFERENCES

1. Patel VB, Zhong JC, Grant MB, et al: Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure. *Circ Res* 2016; 118:1313–1326
2. Bader M, Ganten D: Update on tissue renin-angiotensin systems. *J Mol Med (Berl)* 2008; 86:615–621
3. Turner AJ, Hiscox JA, Hooper NM: ACE2: From vasopeptidase to SARS virus receptor. *Trends Pharmacol Sci* 2004; 25:291–294
4. Verdecchia P, Cavallini C, Spanevello A, et al: The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. *Eur J Intern Med* 2020; 76:14–20

5. Yan Y, Liu Q, Li N, et al: Angiotensin II receptor blocker as a novel therapy in acute lung injury induced by avian influenza A H5N1 virus infection in mouse. *Sci China Life Sci* 2015; 58:208–211
6. Yang P, Gu H, Zhao Z, et al: Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. *Sci Rep* 2014; 4:7027
7. Kuba K, Imai Y, Rao S, et al: A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. *Nat Med* 2005; 11:875–879
8. Huang F, Guo J, Zou Z, et al: Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients. *Nat Commun* 2014; 5:3595
9. Rieder M, Wirth L, Pollmeier L, et al: Serum ACE2, angiotensin II, and aldosterone levels are unchanged in patients with COVID-19. *Am J Hypertens* 2021; 34:278–281
10. Osman IO, Melenotte C, Brouqui P, et al: Expression of ACE2, soluble ACE2, angiotensin I, angiotensin II and angiotensin-(1-7) is modulated in COVID-19 patients. *Front Immunol* 2021; 12:625732
11. Kutz A, Conen A, Gregoriano C, et al: Renin-angiotensin-aldosterone system peptide profiles in patients with COVID-19. *Eur J Endocrinol* 2021; 184:543–552
12. Ozkan S, Cakmak F, Konukoglu D, et al: Efficacy of serum angiotensin II levels in prognosis of patients with coronavirus disease 2019. *Crit Care Med* 2021; 49:e613–e623
13. Ougaard ME, Jensen HE, Thuen ID, et al: Inhibitors of the renin-angiotensin system ameliorates clinical and pathological aspects of experimentally induced nephrotoxic serum nephritis. *Ren Fail* 2018; 40:640–648
14. Jacobs JD, Wagner T, Gulotta G, et al: Impact of angiotensin II signaling blockade on clinical outcomes in patients with inflammatory bowel disease. *Dig Dis Sci* 2019; 64:1938–1944
15. Johansen ME, Yun J, Griggs JM, et al: Anti-hypertensive medication combinations in the United States. *J Am Board Fam Med* 2020; 33:143–146
16. Murphy DP, Drawz PE, Foley RN: Trends in angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use among those with impaired kidney function in the United States. *J Am Soc Nephrol* 2019; 30:1314–1321
17. Ibrahim SL, Jiroutek MR, Holland MA, et al: Utilization of angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) in patients diagnosed with diabetes: Analysis from the National Ambulatory Medical Care Survey. *Prev Med Rep* 2016; 3:166–170
18. Duarte M, Pelorosso F, Nicolosi LN, et al: Telmisartan for treatment of COVID-19 patients: An open multicenter randomized clinical trial. *EClinicalMedicine* 2021; 37:100962
19. Cohen JB, Hanff TC, William P, et al: Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: A prospective, randomised, open-label trial. *Lancet Respir Med* 2021; 9:275–284
20. The Global Health 50/50 Research Initiative: The COVID-19 Sex-Disaggregated Data Tracker June Update Report. 2021. Available at: <https://covid19.who.int/>. Accessed July 12, 2021
21. The Global Health 50/50 Research Initiative: The COVID-19 Sex-Disaggregated Data Tracker. 2021. Available at: <https://globalhealth5050.org/the-sex-gender-and-covid-19-project/the-data-tracker/?explore=country&country=Canada#search>. Accessed July 9, 2021
22. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, et al: Impact of sex and gender on COVID-19 outcomes in Europe. *Biol Sex Differ* 2020; 11:29
23. Naz MSG, Banaei M, Dashti S, et al: An overview of sex hormones in relation to SARS-CoV-2 infection. *Future Virol* 2021 Jul 20. [Epub ahead of print]
24. Haitao T, Vermunt JV, Abeykoon J, et al: COVID-19 and sex differences: Mechanisms and biomarkers. *Mayo Clin Proc* 2020; 95:2189–2203
25. Crackower MA, Sarao R, Oudit GY, et al: Angiotensin-converting enzyme 2 is an essential regulator of heart function. *Nature* 2002; 417:822–828
26. Anguiano L, Riera M, Pascual J, et al: Circulating ACE2 in cardiovascular and kidney diseases. *Curr Med Chem* 2017; 24:3231–3241
27. Soro-Paavonen A, Gordin D, Forsblom C, et al; FinnDiane Study Group: Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. *J Hypertens* 2012; 30:375–383
28. Fernández-Atucha A, Izagirre A, Fraile-Bermúdez AB, et al: Sex differences in the aging pattern of renin-angiotensin system serum peptidases. *Biol Sex Differ* 2017; 8:5
29. Fagyay M, Kertész A, Siket IM, et al: Level of the SARS-CoV-2 receptor ACE2 activity is highly elevated in old-aged patients with aortic stenosis: Implications for ACE2 as a biomarker for the severity of COVID-19. *Geroscience* 2021; 43:19–29
30. Canadian Institutes of Health Research: Sex As a Biological Variable Supplement - Host Response Mediators in Coronavirus (COVID-19) Infection. Funding Decis Database. 2020. Available at https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=424673&lang=en. Accessed August 16, 2021
31. Marshall JC, Murthy S, Diaz J, et al: A minimal common outcome measure set for COVID-19 clinical research. *Lancet Infect Dis* 2020; 20:e192–e197
32. Marshall JC, Vincent JL, Guyatt G, et al: Outcome measures for clinical research in sepsis: A report of the 2nd Cambridge colloquium of the International Sepsis Forum. *Crit Care Med* 2005; 33:1708–1716
33. Russell JA, Lee T, Singer J, et al: Days alive and free as an alternative to a mortality outcome in pivotal vasopressor and septic shock trials. *J Crit Care* 2018; 47:333–337
34. Laterre PF, Berry SM, Blemings A, et al; SEPSIS-ACT Investigators: Effect of seleepressin vs placebo on ventilator- and vasopressor-free days in patients with septic shock: The SEPSIS-ACT randomized clinical trial. *JAMA* 2019; 322:1476–1485
35. Russell JA, Walley KR, Singer J, et al; VASST Investigators: Vasopressin versus norepinephrine infusion in patients with septic shock. *N Engl J Med* 2008; 358:877–887
36. Percy AJ, Mohammed Y, Yang J, et al: A standardized kit for automated quantitative assessment of candidate protein biomarkers in human plasma. *Bioanalysis* 2015; 7:2991–3004
37. Mohammed Y, Bhowmick P, Smith DS, et al: PeptideTracker: A knowledge base for collecting and storing information

- on protein concentrations in biological tissues. *Proteomics* 2017; (17)7
38. Feroze RA, Azam T, Shadid H, et al: Abstract 17228: Gender differences in treatment and outcomes of patients with COVID-19 respiratory failure. *Circulation* 2020; 142:A17228
 39. Lee T, Cau A, Cheng MP, et al; ARBs CORONA: Angiotensin receptor blockers and angiotensin-converting enzyme inhibitors in COVID-19: Meta-analysis/meta-regression adjusted for confounding factors. *CJC Open* 2021; 3:965–975
 40. Geriak M, Haddad F, Kullar R, et al: Randomized prospective open label study shows no impact on clinical outcome of adding losartan to hospitalized COVID-19 patients with mild hypoxemia. *Infect Dis Ther* 2021; 10:1323–1330
 41. Bengtson C, Montgomery R, Nazir U, et al: An open label trial to assess safety of losartan for treating worsening respiratory illness in COVID-19. *Front Med (Lausanne)* 2021; 8:630209
 42. Rabi DM, Khan N, Vallee M, et al: Reporting on sex-based analysis in clinical trials of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker efficacy. *Can J Cardiol* 2008; 24:491–496
 43. Lucas JM, Heinlein C, Kim T, et al: The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. *Cancer Discov* 2014; 4:1310–1325
 44. Leisman DE, Mehta A, Thompson BT, et al: Alveolar, endothelial, and organ injury marker dynamics in severe COVID-19. *Am J Respir Crit Care Med* 2022; 205:507–519
 45. Gerard L, Lecocq M, Bouzin C, et al: Increased angiotensin-converting enzyme 2 and loss of alveolar type II cells in COVID-19-related acute respiratory distress syndrome. *Am J Respir Crit Care Med* 2021; 204:1024–1034
 46. Tan BK, Mainbourg S, Friggeri A, et al: Arterial and venous thromboembolism in COVID-19: A study-level meta-analysis. *Thorax* 2021; 76:970–979